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Abstract
Background: Development of metastasis in breast cancer is a multi-step process comprising
changes in cytoskeletal structure and gene expression of tumour cells leading to changes in cell
adhesion and motility. The Rho GTPase proteins, which function as guanine nucleotide regulated
binary switches, govern a variety of cellular processes including cell motility and migration, changes
in cell adhesion as well as actin cytoskeletal reorganisation and gene expression/transcription. One
group of activators which regulate the Rho-GTPases is the guanine nucleotide exchange factors
(GEFs), and this study looked at three such GEFs, Trio, Vav1 and TIAM-1. The purpose of this study
was to investigate the expression of these GEFs, in human breast cancer and assess the affect on
clinical outcome.
Methods: Specimens of fresh, frozen breast tumour tissue (n = 113) and normal background tissue
(n = 30) were processed for quantitative PCR analysis. The expression and levels of expression of
Trio, Vav1 and TIAM-1 were analysed using RT-PCR and real-time Q-PCR respectively. Sections
were also immunostained with Trio and Tiam-1 antibodies.
Results: Tumour tissue exhibited high levels of all three Rho activators Trio, Vav1 and TIAM-1
compared with normal background breast tissue, reaching a level of significance for the GEF Trio
(p = 0.013). Trio levels also increased significantly in patients with a poor prognostic index (p =
0.04).
Levels of TIAM-1 were significantly higher in tumour tissue from patients who died from breast
cancer compared with those who survived (p = 0.04). No significant correlation was found between
tumour grade and histology types.
Conclusion: High expression levels of Trio, Vav1 and TIAM-1 were seen in breast tumours,
especially in those with poor prognosis. This suggests that aberrant regulation of Rho family
activities by GEFs may have an important prognostic value in breast cancer.
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Background
During the development of metastasis in breast cancer,
tumour cells undergo numerous changes in their cytoskel-
etal structure and gene expression promoting changes in
cell adhesion, motility and morphology leading to metas-
tasis and tissue invasion. The Rho GTPases, which func-
tion as guanine nucleotide regulated binary switches,
control the regulation of the actin cytoskeleton, and as
such, have been implicated in promoting a variety of cel-
lular processes including cell motility and migration,
changes in cell adhesion as well as actin cytoskeletal reor-
ganisation [1-3] and gene expression/transcription [4].
Increased expression of Rho proteins has been demon-
strated in a variety of tumours with raised levels of Rho-C,
Rho-G and Rho-6 detected in breast tumour tissue [5], as
well as increase in the expression of the ROCK proteins,
which function as downstream effectors of the Rho
GTPases [6]. Therefore this study was initiated to investi-
gate the expression levels of the activators of the Rho-
GTPase cycle.
In part, the Rho-GTPases are activated by guanine nucle-
otide exchange factors (GEFs), a group of regulators which
function as modulators of the activation/inactivation
cycle of the Rho family GTPases by binding to inactive
GTPases and inducing a conformational change leading
to GDP release. The GTPases then bind free cytoplasmic
GTP to become reactivated.
There are a large number of guanine nucleotide-binding
proteins requiring an equally large range of GEFs to
ensure signalling specificity and, as such, a number of GEF
families exist. A recent review of the GEFs and GAPs
(GTPase activating proteins), which both function as reg-
ulators of the Rho GDP/GTP cycle, has suggested that
these proteins may be potential therapeutic targets for
developing drug treatments for various cancers [7]. Three
such GEFs which regulate the Rho family of GTPases are
Trio, Vav1 and TIAM-1 (T-lymphoma invasion and metas-
tasis gene).
Trio acts as a cytoskeletal modulator activating the Rho
and/or Rac pathways and has been shown to play a vital
role in axon guidance, neuronal cell migration and cell
motility [8] as well as in the regulation of focal adhesion
dynamics [9].
The Vav family of guanine nucleotide exchange factors
have been shown to modulate activity of Rho, Rac and/or
Cdc42 to effect changes in cytoskeletal organisation [10].
Vav proteins couple tyrosine kinase signals with the acti-
vation of the Rho-GTPases and are likely to play an inte-
gral role in the regulation of cell differentiation in many
tissues. Vav1 has been shown to function as an oncogene
involved in malignant transformation. This protein also
acts as a growth stimulatory protein in primary pancreatic
adenocarcinoma. [11].
Studies have shown that over expression of TIAM-1 pro-
tein confers an invasive phenotype in T-lymphoma cells
suggesting that increased TIAM-1 levels may lead to
tumour progression and invasion [12]. This GEF has also
been shown to interact with the cytoskeletal protein
ankyrin which promotes Rac activation leading to breast
tumour cell invasion and migration [13].
To look for evidence to support their role in the motility
and invasion of breast tumour cells we have analysed the
expression of the Rho GTPase regulators Trio, Vav1 and
TIAM-1 in normal breast tissue and compared this with
the expression in breast tumour tissue and with the grade
of tumour and clinical outcome.
Methods
Surgical specimens of fresh, frozen breast tissue compris-
ing breast tumours (n = 113) and normal background tis-
sue (n = 30) were collected during surgery. Information
was available on the Nottingham Prognostic Index (NPI),
grade of tumour, degree of nodal involvement and clinical
outcome for all patients with a mean follow up period of
72.2 months. The expression and levels of expression of
Trio, Vav1 and TIAM-1 were analysed using RT-PCR and
real-time quantitative PCR respectively.
RNA extraction and RT-PCR
RNA was isolated from breast cancer cell and tissue lines
using a standard RNA-zol procedure, as we previously
reported [6]. For RT-PCR, cDNA was synthesised in a 25
μl reaction mixture, as described in the manufacturer's
protocol (ABgene Reverse Transcription System, ABgene,
Surrey, UK). The cDNA obtained was amplified by a
standard PCR mixture (as supplied in Pre-aliquoted
Reddy-Load Mix, Advanced Biotechnologies). Cycling
conditions for the 25 μl reaction mix were 94°C for 4 min,
followed by 36 cycles of 94°C for 15 s, 55°C annealing for
15 s and 72°C for 30 s, followed by a final extension of 7
min at 72°C. The products were visualised on a 0.8% aga-
rose gel following staining with ethidium bromide.
Quantitative-PCR analysis
The Q-PCR system used the Amplifluor™ Uniprimer™ sys-
tem (Intergen Company Oxford, UK) and Thermo-Start®
(ABgene, Epsom, Surrey, UK) [5,6]. Specific primers were
designed by the authors and manufactured by Invitrogen
(Invitrogen Life Technologies, Paisley, Scotland, UK).
Using the Icycler IQ system (Bio-Rad, Hemel Hempstead,
UK), which incorporates a gradient thermocycler and a
96-channel optical unit, the plasmid standards and breast
cancer cell cDNA were simultaneously assayed in dupli-International Seminars in Surgical Oncology 2008, 5:23 http://www.issoonline.com/content/5/1/23
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cated 10 μl reactions as follows: Q-master mix (5 μl), for-
ward primer (0.3 μl), probe (0.3 μl), reverse primer (0.3
μl), plasmid, (internal standard) or specimen cDNA (4
μl), water (0.1 μl). Q-PCR conditions were as follows:
enzyme activation at 95°C for 12 min, 1 cycle, followed
by 60 cycles of denaturing: 95°C for 15 s; annealing: 55°C
for 40 s; extension: 72°C for 25 s. Using purified plasmids
as internal standards, the level of each molecule cDNA
(copies/50 ng RNA) in the breast cancer samples was cal-
culated. Q-PCR for β-actin was also performed on the
same samples, to correct for any residual differences in the
initial level of RNA in the specimens (in addition to spec-
trophotometry). The products of Q-PCR were verified on
agarose gels. Primer pairs for Q-PCR were as follows: Trio
F1 (5'-accgttgttcttagatgtcg); Trio ZR (5'-actgaacctgaccgta-
caggagatgctgtagtgaccat; Vav1 F1 (5'-agtctctggacaccacctt);
Vav1 ZR (5'-actgaacctgaccgtacaccaaaatactttgtgcttcc); TIAM-
1 F1 (5'-ctttaagaagaaacgctccca); TIAM-1 ZR (5'-actgaacct-
gaccgtacacttggctcagatcagagagt).
Immunohistochemistry
Frozen sections of breast tumour and background tissue
were cut with a cryostat at a thickness of 6 μm. The sec-
tions were mounted on super frost plus microscope slides,
air dried and then fixed in a mixture of 50% acetone and
50% methanol. The sections were then placed in "Opti-
max" wash buffer for 5 – 10 minutes to rehydrate and
incubated for 20 mins in a 0.6% BSA blocking solution
and probed with either Trio (sc-6060) or Tiam-1 (sc-872)
primary antibody (Santa Cruz Biotechnologies Inc., CA,
USA). Following extensive washings in buffer, sections
were incubated for 30 min in the secondary biotinylated
antibody (Multilink Swine anti-goat/mouse/rabbit
immunoglobulin, Dako Inc.). Following washings, Avi-
din/Biotin Complex (Vector Laboratories) was applied to
the sections followed by extensive washings. Diamino
benzidine chromogen (Vector Labs) was then added to
the sections which were incubated in the dark for 5 min.
Sections were counterstained in Gill's Haematoxylin and
dehydrated in ascending grades of methanol before clear-
ing in xylene and mounting under a cover slip.
Statistical analysis
Statistical analysis was performed with MINITAB version
11.2 (Minitab Inc., State College, PA) using two sample
Student's t-tests.
Results
Aberrant expression of TRIO, VAV1 and TIAM-1 in human 
breast cancer
Tumour tissue exhibited significantly high levels of Trio,
when compared with normal background breast tissue
(171.5 ± 46.7 v 82.0 ± 45; p = 0.013). Levels of Vav 1 and
TIAM-1 were also higher in tumours but were not signifi-
cantly different (0.66 ± 0.35 v 0.07 ± 0.027; p = 0.095 for
Vav1 and 1196 ± 743 v 261 ± 107; p = 0.22 for TIAM-1)
(Figure 1). These results were confirmed for Trio and
TIAM-1 by immunohistochemistry staining (Figure 2);
with very little staining seen in normal background tissue
(Figure 2A) while tumour tissue stained strongly for both
Trio and TIAM-1 (Figure 2B). This difference of staining
intensity between normal and tumour tissue is shown in
Figure 2C.
The expression levels of all three GEFs, assessed by Q-PCR,
were compared with a series of predictive factors (Tables
1, 2, 3). Trio levels were seen to increase significantly with
an increase in Nottingham Prognostic Index (109 ± 44
NPI1; 234 ± 113 NPI2; 315 ± 176 NPI3 p = 0.04 compar-
ing NPI1 and NPI2) Figure 3.
Expression of Vav1 showed no definitive pattern, increas-
ing in NPI2 tumours compared with NPI1 tumours but
showing no change in NPI3 tumours (mean ± SEM 0.45 ±
0.22 NPI1; 1.18 ± 1.06 NPI2; 0.45 ± 0.41 NPI3). TIAM-1
expression showed a sequential decrease with increase in
NPI status (1957 ± 1466 NPI1; 506 ± 205 NPI2; 298 ± 123
NPI3) however these changes did not reach a level of sig-
nificance (p > 0.3 in all cases) Table 1.
TIAM-1 expression increased with tumour-node-metasta-
sis status (mean ± SEM 430 ± 117 TNM1 and 2613 ± 2245
TNM2 p = 0.34), as did Vav1 levels (mean ± SEM 0.407 ±
0.22 TNM 1 and 1.28 ± 1.04 TNM 2 p = 0.42) however,
Trio expression showed an increase from TNM1 to TNM3
(160 ± 50 TNM1 and 669 ± 554 TNM4 p = 0.39) but a
decrease in Trio expression in TNM2 tumours (117 ± 62)
Table 2.
Expression levels of the three GEFs studied were also
related to the follow-up data available on clinical out-
come for the patients (Table 3). Based on the outcomes of
the follow up data, patients were grouped into those who
were disease free; with metastatic disease; with local recur-
rence of breast cancer, and died as a consequence of breast
cancer. Trio levels showed little change of expression
between those patients who survived and those who died
from their breast cancer (mean ± SEM 174.1 ± 62.1 surv 1;
263 ± 151 surv 2; 152.4 ± 94.5 surv 3; 188.6 ± 97.2 surv
4). Vav1 showed the highest expression in patients who
remained disease free (0.89 ± 0.48) with much lower
expression in those patients with metastatic disease (0.01
± 0.003); with local recurrence (0.02 ± 0.012) and in
patients who died from breast cancer (0.03 ± 0.016). Lev-
els of TIAM-1 were much lower in tumour tissue from
patients who remained disease free compared with those
who died from breast cancer (median value disease free,
60.3 v median value died from breast cancer, 224.5; p =
0.04, with range Q1–Q3 disease free 0 – -251.1; died from
breast cancer 0 – -3.2).International Seminars in Surgical Oncology 2008, 5:23 http://www.issoonline.com/content/5/1/23
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Levels of expression of Trio, Vav1 and TIAM-1 in tumour and normal background breast tissue Figure 1
Levels of expression of Trio, Vav1 and TIAM-1 in tumour and normal background breast tissue. Comparison of 
levels of Trio, Vav1 and TIAM-1 in tumour samples compared with normal background tissue (expressed as transcript copy 
number per 50 μg of messenger RNA).
*p=0.013 International Seminars in Surgical Oncology 2008, 5:23 http://www.issoonline.com/content/5/1/23
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Immunohistochemical staining of TIAM-1 and Trio in tumour and normal background breast tissue Figure 2
Immunohistochemical staining of TIAM-1 and Trio in tumour and normal background breast tissue. Staining of 
TIAM-1 (left panel) and Trio (right panel) in normal background tissue (A) and in breast tumour tissue (B). Distribution of stain-
ing of TIAM-1 and Trio in tumour and surrounding normal tissue (C).International Seminars in Surgical Oncology 2008, 5:23 http://www.issoonline.com/content/5/1/23
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Comparison of tumour types showed lower levels of Trio
(p = 0.33) and TIAM-1 (p = 0.37) but higher levels of Vav1
(p = 0.47) in ductal tumours than in all other tumour
types Table 4.
Discussion
The guanine nucleotide exchange factors TRIO, VAV1 and
TIAM-1 activate the Rho-GTPases by initiating GDP/GTP
exchange. The GEF Trio is associated with cell motility by
regulation of FAK and effects changes in the actin cytoskel-
eton. This study has shown for the first time that Trio lev-
els are significantly raised in breast tumour tissue
compared with normal tissue (p = 0.013) and higher lev-
els of Trio are also found in tumours with a poor predic-
tive outcome (NPI > 5.4) (p = 0.04). This pattern is
confirmed by immunohistochemical staining.
Vav1 functions as an oncogene involved in malignant
transformation [14] and the Vav family appears to play an
essential role in angiogenesis [15] and androgen receptor
transcriptional activity in prostate cancer [16]. It is
expressed in human neuroblastomas originating from tis-
sues which do not normally express this protein [17]. The
results of our study show that Vav 1 expression was higher
in tumour tissue than in normal background tissue but
this did not reach a level of significance (p = 0.095). Vav
1 over expression has been previously shown to be associ-
ated with poorer survival (9,10) however our study indi-
cates that decreased levels of Vav 1 are associated with
poorer survival (p = 0.07 in all cases).
Higher grade breast tumours have a higher expression of
TIAM-1 which can disturb intercellular adhesiveness by
inducing cellular ruffles and may be correlated with the
invasive phenotypes of human breast tumours [18]. The
results of our study would tend to agree with this finding
as we have shown that TIAM-1 expression is higher in
Levels of expression of Trio in relation to NPI status Figure 3
Levels of expression of Trio in relation to NPI status. 
Trio levels increased sequentially with an increase in the 
Nottingham Prognostic Index.
Table 1: Expression levels of the GEFs studied related to NPI 
status of the tumours
Guanine Nucleotide Exchange Factors
NPI status TRIO VAV1 TIAM-1
(NPI < 3.4) 109 ± 44 0.45 ± 0.22 1957 ± 1466
(NPI 3.4–5.4) 234 ± 113 1.18 ± 1.06 506 ± 205
(NPI > 5.4) 315 ± 176 0.45 ± 0.41 298 ± 123
NPI = Nottingham Prognostic Index.
Levels of Trio showed a sequential increase with increased NPI status 
with a significant increase from NPI1 to NPI2 (p = 0.04). Expression of 
Vav1 showed no definitive pattern while TIAM-1 expression showed a 
sequential decrease with an increase in NPI status.
Table 2: Expression levels of the three GEFs studied related to 
tnm status
Guanine Nucleotide Exchange Factors
TNM status TRIO VAV1 TIAM-1
1 160 ± 50.5 0.41 ± 0.22 430 ± 117
2 116.5 ± 61.6 1.28 ± 1.04 2613 ± 2245
3 669 ± 544 0.148 ± 0.12 2022 ± 1817
tnm = tumour-node-metastasis.
TIAM-1 expression increased with tumour-node-metastasis (tnm) 
status as did Vav1 levels however, Trio expression showed an 
increase from tnm1 to tnm3 (160 ± 50 tnm1 and 669 ± 554 tnm4 p = 
0.39) but a decrease in Trio expression in tnm2 tumours (117 ± 62).
Table 3: Expression levels of the three GEFs studied related to 
clinical outcome
Guanine Nucleotide Exchange Factors
Survival status TRIO VAV1 TIAM-1
1 Disease free 174.1 ± 62.1 0.89 ± 0.48 60.3
2 Metastatic disease 263 ± 151 0.01 ± 0.003 169
3 Local recurrance 152.4 ± 94.5 0.02 ± 0.012 26
4 Died from breast cancer 188.6 ± 97.2 0.03 ± 0.016 225
Trio levels show little change of expression between patients who 
survived and patients who died from breast cancer. Vav1expression 
was highest in patients who remained disease free while TIAM-1 
expression was much lower in patients who remained disease free 
compared with those who died from breast cancer.International Seminars in Surgical Oncology 2008, 5:23 http://www.issoonline.com/content/5/1/23
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tumour tissue than in normal background breast tissue,
although this did not reach a level of significance (p =
0.22). The results from immunohistochemical staining
agree with this finding. However when looking at clinical
outcome for these patients, levels of TIAM-1 were signifi-
cantly higher in tumour tissue from patients who died
from breast cancer compared with those who survived p =
0.04.
Conclusion
High levels of expression of all three GEFs studied Trio,
Vav1 and TIAM-1 were seen in breast tumours compared
with normal background breast tissue. The statistical evi-
dence in this study leads to the conclusion that the GEF
TRIO may be particularly useful as a prognostic factor in
breast cancer as its level is significantly increased in
tumour tissue with Tiam-1 showing a significant increase
in tumour tissue from patients with poor prognosis. This
suggests that aberrant regulation of Rho family activities
by GEFs may have an important prognostic value in breast
cancer and that these GEFs may be important targets for
therapeutic intervention.
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